LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: A long-term comparative cohort study

Human Reproduction

Volumn 28, Issue 11, 2013, Pages 2966-2971

  Gallos, Ioannis D ^a   Krishan, Preeti ^a   Shehmar, Manjeet ^a   Ganesan, Raji ^b   Gupta, Janesh K ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

endometrial hyperplasia; LNG IUS; oral progestogens; prospective cohort study

Indexed keywords

GESTAGEN; LEVONORGESTREL; TAMOXIFEN;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; ENDOMETRIAL THICKNESS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HYSTERECTOMY; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARITY; SURVIVAL;

ENDOMETRIAL HYPERPLASIA; LNG-IUS; ORAL PROGESTOGENS; PROSPECTIVE COHORT STUDY;

ADMINISTRATION, ORAL; ADULT; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; HYSTERECTOMY; INTRAUTERINE DEVICES; LEVONORGESTREL; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; PROGESTINS;

EID: 84885912385     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det320     Document Type: Article

References (24)

1. Akesson E,Gallos ID,GanesanR,VarmaR,Gupta JK. Prognostic significanceof oestrogen and progesterone receptor expression and others in LNG-IUS (Mirenaw) treatment of endometrial hyperplasia: An immunohistochemical study. Acta Obstet Gynecol Scand 2010;89:393-398.
2. Allison KH, Tenpenny E, Reed SD, Swisher EM, Garica RL. Immunohistochemical markers in endometrial hyperplasia: Is there a panel with promise? A review. Appl Immunohistochem Mol Morphol 2008; 16:329-343.
3. Bray F, Dos SSI, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005;14:1132-1142.
4. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: An evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006;125:259-264.
5. Cox DR. Regression models and life tables. J R Stat Soc 1972;34: 187- 220.
6. Gallos ID, Shehmar M, ThangaratinamS, Papapostolou TK, Coomarasamy A, Gupta JK.Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: A systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1-e10.
7. Gallos ID, Ofinran O, Shehmar M, Coomarasamy A, Gupta JK. Current management of endometrial hyperplasia-a survey of United Kingdom consultant gynaecologists. Eur J Obstet Gynecol Reprod Biol 2011;158:305-307.
8. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. Relapse of endometrial hyperplasia after conservative treatment: A cohort study with long term follow up. Hum Reprod 2013a;28:1231-1236.
9. Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia treated with conservative therapy: A cohort study. Obstet Gynecol 2013b;121:1165-1171.
10. Gallos ID, Ganesan R, Gupta JK. ER, PR, COX-2, MLH1, and BCL-2 expression predicting regression and relapse of endometrial hyperplasia treated with LNG-IUS (Mirenaw): A cohort study. Gynecol Oncol 2013c; 130:1165-1171.
11. HosmerDWJr, Lemeshow S. Applied Logistic Regression, 2nd edn.NewYork: Wiley, 2000.
12. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer 1959;12:1106-1122.
13. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of ?untreated? hyperplasia in 170 patients. Cancer 1985; 56:403-412.
14. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; CD002126.
15. Lin DY, Wei JL. The robust inference for the Cox proportional hazards model. J Am Statist Assoc 1989;84:1074-1078.
16. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982;17:529-536.
17. Office for National Statistics. Cancer Statistics registrations: Registrations of Cancer Diagnosed in 2007, England. National Statistics (Series MB1 No. 38). London, 2010.
18. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73.
19. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF, Weiss NS. Incidence of endometrial hyperplasia.AmJ Obstet Gynecol 2009; 200:678.e1-6.
20. Rubin DB. A non-iterative algorithm for least squares estimation of missing values in any analysis of variance design. J R Stat Soc 1972; 21:136-141.
21. Schafer JL. Analysis of Incomplete Multivariate Data. London: Chapman &Hall/CRC, 1997.
22. Tavassoli FA.World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press, 2003
23. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, Alberts D, Cutin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: A Gynecologic Oncology Group study. Cancer 2006;106:812-819.
24. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-175.